Stemtech Corporation (STEK)
OTC PINK OTC PINK Primary 
Stemtech Corporation / Viago and Eevia Health Announce Proposed RTO
NAPLES, FL / ACCESSWIRE / December 5, 2024 / Stemtech Corporation (OTCQB:STEK), a US-based company announced this past Tuesday its planned merger ("Merger") with Seacret Direct, LLC ("VIÁGO") and now announces a proposal for a Reverse Takeover (RTO) of Eevia Health Plc ("Eevia"), a Finnish producer of bioactive organic Arctic plant extracts and nutraceuticals and has its common stock listed on the Swedish Spotlight Stock Market under the symbol "EEVIA". This strategic RTO marks a major milestone in the evolution of the combined companies, intending to create a vertically integrated health, wellness, and lifestyle entity that manufactures its own products and is positioned for significant growth in the global marketplace.
Stemtech Corporation and Seacret Direct / Viago Execute Merger Agreement
NAPLES, FL / ACCESSWIRE / December 4, 2024 / Stemtech Corporation (OTCQB:STEK) is pleased to announce the merger agreement with Seacret Direct / VIÁGO, progressing their plan to establish a global leadership position in defining the future of lifestyle, health and longevity. The transaction will be completed through the issuance of 13 million preferred shares with a stated value of $2.50 per share.
Stemtech Corporation and Viago Announce Strategic Merger
NAPLES, FL / ACCESSWIRE / November 20, 2024 / Stemtech Corporation (OTCQB:STEK) and Seacret Direct, LLC (doing business as VIÁGO) are pleased to announce they have reached an agreement in principle to merge their businesses. This merger represents a transformative step forward for both organizations, aiming to drive significant growth and enhance shareholder value.
Stemtech Corporation Announces Uplist to OTCQB, Maintains Focus on Expansion and Transparency
NAPLES, FL / ACCESSWIRE / September 4, 2024 / ("STEK") Stemtech Corporation, the pioneer and trailblazer in the stem cell nutrition sector, is proud to announce that OTC Markets has approved us to quote as an OTCQB stock, symbolizing a commitment to transparency and investor confidence. As we consolidate our footprint in the United States, Mexico, Ecuador, Canada and Taiwan, this milestone is a testament to our dedication to global health through groundbreaking stem cell nutrition, skin care, oral care and as recently announced on August 22, pet care technologies.
Stemtech Expands Into The $303 Billion Pet Health Care Market With Launch Of Stempets(TM)
NAPLES, FL / ACCESSWIRE / August 22, 2024 / Stemtech Corporation (OTCQB;STEK), a leader in the development and distribution of stemceutical™ products for humans offered since 2005, is proud to announce an exciting new product line into the pet health care industry with the launch of "StemPets™." This revolutionary product is designed to provide substantial health benefits to dogs, cats, and other beloved pets, tapping into the $303 billion pet health care market.
